HEALTHCARE

The Peptide Landscape in 2026

6 min. read

A peptide is a short chain of amino acids joined by peptide bonds, is typically fewer than about 50 amino acids long, and thus differs from a larger protein. More importantly, peptides act as chemical messengers, binding to receptors on cells to signal how those cells and tissues should function. Today, peptides range from FDA-approved prescription drugs, such as the GLP-1 medications semaglutide and tirzepatide, to largely unapproved wellness compounds like BPC-157 that are marketed online for recovery and anti-aging. To say that peptides have moved from a quiet niche into mainstream demand would be an understatement. Clinics, telehealth startups, compounding pharmacies, and supplement brands repeatedly face the same fundamental question: are these products legal to sell? The answer to that depends entirely on the specific peptide and how it reaches the patient, as federal law classifies peptides into distinct categories governed by entirely different rulebooks.

What the Clinical Research Shows

The legal distinctions matter partly because the underlying clinical evidence varies significantly. Over the past five years, the New England Journal of Medicine and JAMA have published randomized clinical trials on several therapeutic peptides outside the weight-loss sector, yielding mixed outcomes. In a 2024 NEJM trial, rusfertide, a synthetic version of the iron-regulating hormone hepcidin, helped patients with polycythemia vera maintain stable red blood cell levels while requiring far fewer therapeutic phlebotomies than patients taking a placebo. Similarly, a 2025 NEJM trial found that pegcetacoplan, a peptide targeting part of the immune system’s complement cascade, lowered urinary protein excretion in patients suffering from rare kidney disorders.

Conversely, other findings have been less promising. A 2021 NEJM trial investigating intranasal oxytocin, a peptide hormone widely promoted for social and emotional enhancement, revealed no significant benefit to social functioning among children and adolescents with autism compared to a placebo. Furthermore, a 2021 JAMA trial demonstrated that administering vasopressin alongside a steroid during in-hospital cardiac arrest successfully restored circulation more frequently but did not improve 30-day survival rates. Popular recovery peptides currently dominating headlines lack comparable data, reflecting the exact evidence gap cited by FDA staff when opposing the inclusion of those peptides on the Bulks List.

Peptides Are Not a Single Regulatory Category

Regulators and industry professionals generally organize these compounds into four separate buckets:

  • First, there are FDA-approved peptide drugs like semaglutide, tirzepatide, and tesamorelin, which are entirely legal when prescribed and dispensed through regulated pharmaceutical channels.
  • Second are compounded peptides prepared by licensed pharmacies for individual patients, meaning they are neither FDA-approved finished drugs nor dietary supplements.
  • Third are experimental peptides like BPC-157, TB-500, and CJC-1295 marketed online despite lacking drug approval or lawful supplement status.
  • Fourth are nutritional peptides derived from food proteins, such as collagen, which can be legally marketed as dietary ingredients provided they comply with the Dietary Supplement Health and Education Act (DSHEA).

The Drug Pathway

If a synthetic peptide is intended to diagnose, cure, mitigate, treat, or prevent a disease, it legally qualifies as a drug under the Federal Food, Drug, and Cosmetic Act (FDCA). Unless it has received explicit FDA authorization, it is classified as an unapproved new drug, rendering commercial distribution for human use unlawful. Furthermore, compounding unapproved peptides or marketing them as “research chemicals” intended for human consumption breaks basic statutory rules that many online vendors routinely overlook.

The Supplement Pathway

DSHEA strictly confines dietary ingredients to categories such as vitamins, minerals, herbs, amino acids, and dietary substances for use by humans to supplement the diet, while classifying injectables as drug products rather than supplements. Currently, peptides do not qualify as dietary ingredients unless they naturally occur within the food supply, meaning synthetic peptides sold as “supplements” usually violate FDA regulations. Additionally, introducing a novel dietary ingredient requires submitting a New Dietary Ingredient (NDI) notification backed by robust safety data, a prerequisite generally bypassed by sellers of oral BPC-157 or GHK-Cu. Collagen and other food-derived bioactive peptides serve as the primary exceptions, assuming they satisfy all DSHEA standards.

The Compounding Pathway, and What Actually Changed in 2026

Under Section 503A of the FDCA, a state-licensed pharmacy or federal facility is permitted to compound a bulk drug substance for a specific patient only if the active ingredient is a component of an FDA-approved drug, is covered by a USP monograph, appears on the 503A Bulks List, or falls within Category 1 of the interim guidance list (with sermorelin and NAD+ serving as prime examples). The FDA previously assigned numerous popular peptides to Category 2, indicating safety concerns and disqualifying them from bulk compounding.

Two big changes in 2026 shook things up, though the laws themselves remained the same. In April 2026, the FDA removed roughly a dozen peptides, including BPC-157 and TB-500, from Category 2 following the withdrawal of their nominations, leaving them without an authorized pathway for 503A compounding pending further FDA action. Subsequently, the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax to the 503A Bulks List while voting against emideltide (DSIP), despite FDA briefing documents favoring their exclusion.

It is important to remember that these committee votes remain strictly advisory. Because recommendations are non-binding, the FDA must still decide whether to begin formal administrative rulemaking, and these substances cannot be lawfully compounded until that process concludes.

The FDA can take a year or more to finish changing a rule, so a “yes” vote from the advisory committee would not make these products legal to sell right away. Characterizing a PCAC vote as an FDA “approval” in marketing copy is legally inaccurate, as the agency has not formally authorized these peptides or added them to the Bulks List. An additional PCAC meeting addressing further peptides is anticipated by February 2027. Ipamorelin, CJC-1295, AOD-9604, and thymosin alpha-1 were the subject of a 2024 lawsuit challenging their Category 2 placement, which ended in a settlement that sent them to the PCAC for review. In late 2024, the PCAC voted against adding any of the four to the Bulks List.

Sourcing and Enforcement

Even when a lawful compounding pathway exists, active pharmaceutical ingredients must originate from an FDA-registered API supplier capable of providing a compliant Certificate of Analysis (CoA), and substances labeled for “research use only” can never be utilized in human compounding. The FDA maintains active enforcement protocols: in July 2026, the proprietor of Paradigm Peptides received a 70-month prison sentence after pleading guilty to unlawful importation and interstate distribution of unapproved new drugs. Practitioners also face professional liability: a licensed provider who recommends substances that do not qualify as legal dietary ingredients may fall below the standard of care, and non-physicians who do the same can prompt state-level unauthorized practice of medicine inquiries. Additionally, because compounded peptides lack FDA approval, they are generally excluded from commercial insurance reimbursement, and several compounds remain listed on the WADA Prohibited List.

The Practical Takeaway

For now, the safest assumption is that it remains illegal to sell popular unapproved peptides for people to use, unless they go through a valid prescription and a properly run compounding pharmacy. Any business thinking about this market should check the exact legal status of each peptide before buying or advertising it. Treat the 2026 advisory votes as a sign of where the rules may be heading, not as permission to start selling today.

Disclaimer: This industry insight is for general information only, is not legal advice, and does not create an attorney-client relationship.

SHARE THIS INSIGHT
Building a peptide product or program?Talk with an attorney and stay ahead of the curve. Early is never too early.
Schedule a consultation
KEEP READING

More insights

All insights →
HEALTHCARE

Diligence Concerns When Investing in Ketamine Clinics

Read more
HEALTHCARE

Telehealth: Cybersecurity Certifications and Frameworks

Read more
HEALTHCARE

DOJ and HHS’s New FCA Pilot Program

Read more
GET IN TOUCH
2875 NE 191st Street, Suite 500
Aventura, FL 33180
42 Broadway, 12th Floor
New York, NY 10004
835 Wilshire Boulevard, Suite 500
Los Angeles, CA 90017
© 2024-2026 Praetorian Legal ServicesAll rights reserved. Attorney advertising.Prior results do not guarantee a similar outcome.